Assuntos
Humanos , Masculino , Feminino , Criança , Amebíase/tratamento farmacológico , Anti-Helmínticos/uso terapêutico , Giardíase/tratamento farmacológico , Helmintíase/tratamento farmacológico , Amebicidas/uso terapêutico , Criptosporidiose/complicações , Hicantone/efeitos adversos , Esquistossomose mansoni/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/complicaçõesAssuntos
Isotiocianatos , Esquistossomose/tratamento farmacológico , Esquistossomicidas/uso terapêutico , Animais , Difenilamina/efeitos adversos , Difenilamina/análogos & derivados , Difenilamina/uso terapêutico , Humanos , Hicantone/efeitos adversos , Hicantone/uso terapêutico , Niridazol/efeitos adversos , Niridazol/uso terapêutico , Oxamniquine/efeitos adversos , Oxamniquine/uso terapêutico , Praziquantel/efeitos adversos , Praziquantel/uso terapêutico , Schistosoma mansoni , Esquistossomicidas/efeitos adversos , Tiocianatos/efeitos adversos , Tiocianatos/uso terapêuticoAssuntos
Hicantone/uso terapêutico , Esquistossomose/tratamento farmacológico , Tioxantenos/uso terapêutico , Adolescente , Animais , Criança , Ensaios Clínicos como Assunto , Enzimas/sangue , Feminino , Humanos , Hicantone/efeitos adversos , Masculino , Contagem de Ovos de Parasitas , Schistosoma mansoni , Índias OcidentaisRESUMO
In a blind trial, 32 schistosomiasis mansoni patients (mean age, 12.03 years) in St. Lucia were given a single intramuscular dose (2.5 mg/kg of body weight) of either hycanthone or a vitamin placebo. The principal side effect, vomiting, was limited to four of the 16 patients given hycanthone; three patients in the hycanthone group and two of the 16 given placebo complained of abdominal pain. Daily enzyme determinations suggest that the mild elevations of serum glutamic oxaloacetic transaminase, lactic dehydrogenase and creatine phosphokinase observed in both groups were due to muscle injury at the injection site. Six months after treatment, only the hycanthone group had a marked reduction in egg excretion (99 percent), with 7/16 then excreting no eggs. The hycanthone group had a greater but statistically insignificant decrease in symptoms at six months. Of 30 patients with hepatomegaly, only the 16 in the hycanthone group showed a statistically significant decrease in liver size at six months; of seven patients with splenomegaly, the two in the hycanthone group and 1/5 in the placebo group showed a decrease in spleen size. All patients gained in weight during the study, with the mean increase for the hycanthone group being greater by 1.2 kg. At the conclusion of the study, the placebo group patients were treated with hycanthone (AU)
Assuntos
Humanos , Criança , Adolescente , 21003 , Masculino , Feminino , Esquistossomose/tratamento farmacológico , Tioxantenos/uso terapêutico , Hicantone/efeitos adversos , Hicantone/uso terapêutico , Schistosoma mansoni , Contagem de Ovos de Parasitas , Enzimas/sangue , Ensaios Clínicos como Assunto , Índias OcidentaisRESUMO
Clinical trials of hycanthone (single intramuscular dose) were undertaken in schistosomiasis mansoni patients in St. Lucia at five dose levels: 3.0, 2.5, 2.0, 1.5, and 1.0 mg/kg body weight. The most common side effect, vomiting, decreased in frequency from 51% at the highest dose to 3% at the lowest; minor side effects showed a similar trend. Three fecal specimens were examined before and at 6 months after treatment by qualitative, quantitative, and hatching techniques. All dose levels caused reductions in egg excretion of 89 to 98%. Rates of cure (absence of eggs by all three methods) according to dose (descending), pretreatment egg output (0-19, 20-49, 50-399, 400+ eggs/ml feces), and age (0-7, 8-14, 15-29, 30+ years) were analyzed to estimate the effect of each variable if the others had been constant. For dose, the standardized percentage success rates were 53.9%, 62.0%, 51.2% 54.0%, and 27.4%; for egg output, 67.0%, 51.8%, 43.2%, and 21.7%; and for age, 25.2%, 34.5%, 59.3% and 57.4%. Logit regression analysis shows a significant difference in cure rate (a) between the lowest dose and all others, among which latter there was no difference, (b) between patients excreting 0 to 49 eggs/ml before treatment and those excreting 50+ eggs/ml, and (c) between the age groups 0 to 14 and 15+ years. All dose levels caused some regression in enlargement of liver or spleen. A dose of 1.5 to 2.0 mg/kg body weight is considered to be as effective as one of 3.0 mg/kg and more acceptable for a control program because of the marked reduction in side effects.
Assuntos
Hicantone/administração & dosagem , Schistosoma mansoni , Esquistossomose/tratamento farmacológico , Tioxantenos/administração & dosagem , Adolescente , Adulto , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Fezes/parasitologia , Feminino , Humanos , Hicantone/efeitos adversos , Hicantone/uso terapêutico , Lactente , Injeções Intramusculares , Masculino , Esquistossomose/parasitologia , Índias OcidentaisRESUMO
Clinical trials of hycanthone (single intramuscular dose) were undertaken in Schistosomiasis mansoni patients in St. Lucia at five dose levels: 3.0, 2.5, 2.0, 1.5, and 1.0mg/kg body weight. The most common side effect, vomiting, decreased in frequency from 51 percent at the highest dose to 3 percent at the lowest; minor side effects showed a similar trend. Three fecal specimens were examined before and at 6 months after treatment by qualitative, quantitative, and hatching techniques. All dose levels caused reductions in egg excretion of 89 to 98 percent. Rates of cure (absence of eggs by all three methods) according to dose(descending), pretreatment egg output (0-19, 20-49, 50-399, 400+ eggs/ml feces), and age (0-7, 8-14, 15-29, 30+ years) were analyzed to estimate the effect of each variable if the others had been constant. For dose, the standardized percentage success rates were 53.9 percent, 62.0 percent, 51.2 percent, 54.0 percent, and 27.4 percent; for egg output, 67.0 percent, 51.8 percent, 43.2 percent, and 21.7 percent; and for age, 25.2 percent, 34.5 percent, 59.3 percent, and 57.4 percent. Logit regression analysis shows a significant difference in cure rate (a) between the lowest dose and all others, among which latter there was no difference, (b) between patients excreting 0 to 49 eggs/ml before treatment and those excreting 50+ eggs/ml, and (c) between the age groups 0 to 14 and 15+ years. All dose levels caused some regression in enlargement of liver and spleen. A dose of 1.5 to 2.0mg/kg body weight is considered to be as effective as one of 3.0mg/kg and more acceptable for a control program because of the marked reduction in side effects. (AU)
Assuntos
Humanos , Lactente , Pré-Escolar , Criança , Adolescente , Adulto , Masculino , Feminino , Hicantone/administração & dosagem , Schistosoma mansoni , Esquistossomose/tratamento farmacológico , Tioxantenos/administração & dosagem , Relação Dose-Resposta a Droga , Fezes/parasitologia , Hicantone/efeitos adversos , Hicantone/uso terapêutico , Injeções Intramusculares , Esquistossomose/parasitologia , Santa LúciaAssuntos
Hicantone/uso terapêutico , Esquistossomose/tratamento farmacológico , Tioxantenos/uso terapêutico , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Humanos , Hicantone/efeitos adversos , Lactente , Masculino , Pessoa de Meia-Idade , Schistosoma mansoni/isolamento & purificação , Esquistossomose/parasitologiaRESUMO
One hundred patients with active schistosomiasis mansoni were treated with niridazole (25 mg/kg/day po for 7 days). The most serious side effects were those connected with the neuropsychic area (convulsion, hallucination, etc.). Therapeutic activity, based on repeated stool examinations, was about 90% in adults and 60% in children. Because of the side effects, as well as the long-term schedule of treatment, niridazole is not recommended for use under field conditions. Seven hundred and forty-five patients were treated with hycanthone (2.5 mg/kg im) after clinical examination. The side effects observed were mild and of short duration (24-48 hr). The therapeutic activity was very high (about 95% cure). So far we have treated more than 9,000 infected patients without severe complications, including hepatic failure and death, which have been reported by some authors. A hycanthone-resistant strain has been isolated from two patients unsuccessfully treated twice with hycanthone and once with niridazole. Considering that an important aspect of the control of schistosomiasis is mass treatment, further studies regarding mutagenicity, teratogenicity, resistance, and toxicological effects of hycanthone are still required before this drug can be recommended for wide use.